Douglas E. Laux

Hematology
200 Hawkins Dr
Iowa City, IA 52242

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond.

The Evolution, Current Landscape, and Future Prospects of Oncolytic Virotherapy in Melanoma: Talimogene Laherparepvec and Beyond.

Journal: Cells
Published: September 16, 2025

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.

A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced cutaneous melanoma.

Journal: Cancer
Published: July 16, 2025

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.

Journal: Journal for immunotherapy of cancer
Published: July 04, 2025

Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab.

Phase I study of allogeneic monocyte-derived inflammatory dendritic cells in combination with pembrolizumab.

Journal: Future science OA
Published: November 20, 2024

Corrigendum to: Time to put it out - nurse-facilitated tobacco treatment in a comprehensive cancer center.

Corrigendum to: Time to put it out - nurse-facilitated tobacco treatment in a comprehensive cancer center.

Journal: Translational behavioral medicine
Published: December 05, 2021

Time to put it out - nurse-facilitated tobacco treatment in a comprehensive cancer center.

Time to put it out - nurse-facilitated tobacco treatment in a comprehensive cancer center.

Journal: Translational behavioral medicine
Published: August 04, 2021

High-specific-activity 131iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.

High-specific-activity 131iodine-metaiodobenzylguanidine for therapy of unresectable pheochromocytoma and paraganglioma.

Journal: Future oncology (London, England)
Published: January 28, 2021

A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma.

A pathogenic germline BRCA2 variant in a patient with hypopharyngeal squamous cell carcinoma.

Journal: Clinical case reports
Published: April 29, 2020

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers.

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers.

Journal: Cancer prevention research (Philadelphia, Pa.)
Published: June 18, 2019

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

A preliminary analysis of interleukin-1 ligands as potential predictive biomarkers of response to cetuximab.

Journal: Biomarker research
Published: March 12, 2019

Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).

Comparing high-dose cisplatin with cisplatin-based combination chemotherapy in definitive concurrent chemoradiation setting for locally advanced head and neck squamous cell carcinoma (LAHNSCC).

Journal: Cancer medicine
Published: December 05, 2018

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma.

Journal: Journal for immunotherapy of cancer
Published: November 14, 2018
Showing 1-12 of 13

Last Updated: 09/26/2026